Company
Leo Pharma As
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
12
10 still marketed
Novel approvals
4
Approvals since 2021
4
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Anzupgo approved NovelJul 23, 2025
- Adbry new use Jun 12, 2024
- Adbry new use Dec 14, 2023
- Adbry approved NovelDec 27, 2021
- Enstilar new use Oct 16, 2020
- Enstilar new use Priority reviewJul 30, 2019
- Taclonex new use Jul 25, 2019
- Enstilar approved Oct 16, 2015
- Finacea approved Jul 29, 2015
- Taclonex new use Dec 23, 2014
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (10)
Newest FDA action first.
- Anzupgo Delgocitinib · 2025
- Adbry Tralokinumab · 2021
- Dovonex Calcipotriene · 1993
- Dovonex Calcipotriene · 1996
- Finacea Azelaic Acid · 2002
- Enstilar Betamethasone Dipropionate, Calcipotriene · 2015
- Finacea Azelaic Acid · 2015
- Taclonex Betamethasone Dipropionate, Calcipotriene, Calcipotriene Hydrate · 2008
- Protopic Tacrolimus · 2000
- Taclonex Betamethasone Dipropionate, Calcipotriene · 2006
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.